Spyre Therapeutics (SYRE) awards director 8,026 options at $72.51

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Michael Thomas Henderson received a grant of stock options covering 8,026 shares of common stock. The options have an exercise price of $72.51 per share and expire on May 27, 2036. They vest and become fully exercisable on the earlier of May 27, 2027 or the company’s 2027 annual meeting of stockholders, subject to his continued service, leaving him with 8,026 options following this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HENDERSON MICHAEL THOMAS

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,026	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,026 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 8,026 options Exercise price: $72.51 per share Post-grant option holdings: 8,026 options +2 more

5 metrics

Option grant size 8,026 options Stock Option (Right to Buy) granted to director

Exercise price $72.51 per share Conversion or exercise price of stock option

Post-grant option holdings 8,026 options Total derivative shares following transaction

Option expiration date May 27, 2036 Expiration of stock option award

Option vesting date trigger Earlier of May 27, 2027 or 2027 annual meeting Vesting condition subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, vest and become fully exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for the derivative grant"

exercise price financial

"conversion_or_exercise_price of 72.5100 per share for the option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become fully exercisable financial

"options "will vest and become fully exercisable" upon the earlier of two dates"

annual meeting of stockholders financial

"vesting tied to "the Issuer's 2027 annual meeting of stockholders""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.51	05/27/2026		A		8,026		(1)	05/27/2036	Common Stock	8,026	$0	8,026	D

Explanation of Responses:

1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Spyre Therapeutics (SYRE) disclose in this Form 4 for Michael Thomas Henderson?

Spyre Therapeutics reported that director Michael Thomas Henderson received a stock option grant for 8,026 shares. The options are a compensation award, not an open-market purchase or sale, and give him the right to buy common stock at a fixed exercise price.

How many Spyre Therapeutics (SYRE) options were granted to Michael Thomas Henderson?

Michael Thomas Henderson was granted stock options covering 8,026 shares of Spyre Therapeutics common stock. This award increases his derivative holdings to 8,026 options following the transaction, according to the Form 4 filing’s post-transaction holdings detail.

What is the exercise price of Michael Thomas Henderson’s Spyre Therapeutics (SYRE) stock options?

The granted stock options have an exercise price of $72.51 per share. This means Henderson can purchase Spyre Therapeutics common stock at $72.51 once the options vest, regardless of the market price at that future time.

When do Michael Thomas Henderson’s Spyre Therapeutics (SYRE) options vest?

The options will vest and become fully exercisable on the earlier of May 27, 2027 or Spyre Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditional on Henderson’s continuous service to the company through the applicable vesting date.

When do Michael Thomas Henderson’s Spyre Therapeutics (SYRE) stock options expire?

The stock options granted to Michael Thomas Henderson expire on May 27, 2036. After that expiration date, he can no longer exercise these options to purchase Spyre Therapeutics common stock at the stated exercise price.

Is Michael Thomas Henderson buying or selling Spyre Therapeutics (SYRE) shares in this Form 4?

This Form 4 shows a grant of stock options, not a market trade. Henderson is acquiring the right to buy 8,026 shares at a set price; there is no open-market purchase or sale of Spyre Therapeutics common stock in this transaction.